1)Smolen JS, et al:EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs;2022 update. Ann Rheum Dis 82:3-18, 2023
2)日本リウマチ学会(編):関節リウマチ診療ガイドライン2020,診断と治療社,2021
3)Yamanaka H, et al:Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort(I). Mod Rheumatol 24:33-40, 2014
4)日本リウマチ学会MTX診療ガイドライン小委員会(編):メトトレキサート(MTX)使用と診療の手引き2023年版,羊土社,2023
5)Pivovarov K, Zipursky JS:Low-dose methotrexate toxicity. CMAJ 191:E423, 2019
6)Dalkilic E, et al:Methotrexate intoxication;Beyond the adverse events. Int J Rheum Dis 21:1557-1562, 2018
7)Salliot C, van der Heijde D:Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis;A systematic literature research. Ann Rheum Dis 68:1100-1104, 2009
8)Gutierrez-Ureña S, et al:Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 39:272-276, 1996
9)Amissah-Arthur MB, Baah W:Methotrexate-induced pancytopenia and mucositis caused by medication error. Ghana Med J 54:68-71, 2020
10)Ajmani S, et al:Methotrexate-induced pancytopenia;A case series of 46 patients. Int J Rheum Dis 20:846-851, 2017
11)Bourré-Tessier J, Haraoui B:Methotrexate drug interactions in the treatment of rheumatoid arthritis;A systematic review. J Rheumatol 37:1416-1421, 2010
12)Romão VC, et al:Three decades of low-dose methotrexate in rheumatoid arthritis;Can we predict toxicity? Immunol Res 60:289-310, 2014
13)猪飼浩樹,滝澤直歩:レジデント・ジェネラリストのためのリウマチ・膠原病診療 痛み・検査・症状から解く診断へのアプローチと押さえておきたい治療戦略,メジカルビュー社,2022
14)Cansu DÜ, et al:How should we manage low-dose methotrexate-induced pancytopenia in patients with rheumatoid arthritis? Clin Rheumatol 37:3419-3425, 2018